PRIMARY STUDY
Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity
Key Findings: Administration of JD5037, which is a CB1R blocker, this study found improved symptoms of cyclophosphamide-induced cystitis in rats, suggesting further studies may lead to therapeutic uses of CB1R blockage in treatment.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Israel
Year of Pub: 2022
Cannabinoids Studied: Synthetic Cannabinoid (unspecified), Endocannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1
Dosage: CB1R antagonist, JD5037 (3 mg/kg)
Route of Administration: Injection
Citation: Hinden L, et al. Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity. Cannabis Cannabinoid Res. 2023; 8:623-633. doi: 10.1089/can.2022.0077
Authors: Hinden L, Ludyansky R, Leidershnaider S, Harris Y, Nemirovski A, Gofrit ON, Tam J, Hidas G
